By Cristina Roca 
 

Bayer AG (BAYN.XE) has agreed to buy the shares in BlueRock Therapeutics it didn't already own, valuing the company at up to $1 billion, it said Thursday.

Bayer, which already held 40.8% in BlueRock, will buy the remaining shares in the biotechnology company for about $240 million in cash and an additional $360 million in milestone payments. It expects the deal to close during the third quarter of 2019.

The German chemical and pharmaceutical giant established BlueRock, which develops engineered cell therapies in the fields of neurology, cardiology and immunology, through a venture with Versant Venture Management LLC (VV.XX) in 2016.

 

Write to Cristina Roca at cristina.roca@dowjones.com; @_cristinaroca

 

(END) Dow Jones Newswires

August 08, 2019 07:29 ET (11:29 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Bayer Aktiengesellschaft (PK) Charts.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Bayer Aktiengesellschaft (PK) Charts.